|
1）Working Group Committee for the Preparation of Guidelines for Peritoneal Dialysis, Japanese Society for Dialysis Therapy. 2009 Japanese society for dialysis therapy guidelines for peritoneal dialysis. Ther Apher Dial. 2010; 14: 489-504
|
|
|
|
2）中山昌明, 伊丹儀友, 金澤良枝, 他．腹膜透析ガイドライン改訂準備委員会報告．透析会誌. 2011; 44(12): 1199-204
|
|
|
|
|
|
3）Hirahara I, Umeyama K, Urakami K, et al. Serial analysis of matrix metalloproteinase-2 in dialysate of rat sclerosing peritonitis models. Clinic Exp Nephrol. 2001; 5: 103-8
|
|
|
|
|
|
4）Hirahara I, Umeyama K, Shofuda K, et al. Increase of matrix metalloproteinase-2 in dialysate of rat sclerosing encapsulating peritonitis model. Nephrology. 2002; 7: 161-9
|
|
|
|
|
5）Hirahara I, Ogawa Y, Kusano E, et al. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transpl. 2004; 19: 1732-41
|
|
|
|
|
|
6）Ertilav M, Timur O, Hur E, et al. What does the dialysate level of matrix metalloproteinase 2 tell us? Adv Perit Dial. 2011; 27: 6-10
|
|
|
|
|
|
7）Hirahara I, Kusano E, Yanagiba S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int. 2006; 26: 380-92
|
|
|
|
|
|
8）Hirahara I, Ishibashi Y, Kaname S, et al. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant. 2009; 24: 437-47
|
|
|
|
|
|
9）Ro Y, Hamada C, Inaba M, et al. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant. 2007; 22: 2838-48
|
|
|
|
|
|
10）Kocak G, Azak A, Astarcl HM, et al. Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats. Ther Apher Dial. 2012; 16: 75-80
|
|
|
|
|
|
11）Saglam F, Cavdar Z, Sarioglu S, et al. Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis. Ren Fail. 2012; 34: 95-102
|
|
|
|
|
|
12）Yildirim A, Ozkan OV, Aslan A, et al. The effects of low-dose erythropoiesis-stimulating agents on peritoneal fibrosis induced by chemical peritonitis and on peritoneal tissue MMP-2 and TIMP-2 Levels in rats. Ren Fail. 2009; 3: 567-72
|
|
|
|
|
|
13）Ucar E, Borazan A, Semerci E, et al. The effects of interferon alpha2b on chemically-induced peritoneal fibrosis and on peritoneal tissue MMP-2 and TIMP-2 levels in rats. J Int Med Res. 2010; 38: 187-94
|
|
|
|
|
|
14）Kurata K, Maruyama S, Kato S, et al. Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice. Am J Physiol Renal Physiol. 2009; 297: F1510-7
|
|
|
|
|
|
15）Hirahara I, Inoue M, Umino T, et al. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: A multicenter study in Japan. Nephrol Dial Transplant. 2011; 26: 1695-701
|
|
|
|
|
|
16）Hirahara I, Inoue M, Okuda K, et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan. Nephrol Dial Transplant. 2007; 22: 560-7
|
|
|
|
|
|
17）Martin J, Yung S, Robson RL, et al. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int. 2000; 20: 524-33
|
|
|
|
|
|
18）Naiki Y, Matsuo K, Matsuoka T, et al. Possible role of hepatocyte growth factor in regeneration of human peritoneal mesothelial cells. Int J Artif Organs. 2005; 28: 141-9
|
|
|
|
|
|
19）Haslinger B, Mandl-Weber S, Sitter T. Thrombin suppresses matrix metalloproteinase 2 activity and increases tissue inhibitor of metalloproteinase 1 synthesis in cultured human peritoneal mesothelial cells. Perit Dial Int. 2000; 20: 778-83
|
|
|
|
|
|
20）Margetts PJ, Bonniaud P, Liu L, et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol. 2005; 16: 425-36
|
|
|
|
|
|
21）Osada S, Hamada C, Shimaoka T, et al. Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol Dial Transplant. 2009; 24: 3504-12
|
|
|
|
|
|
22）Morishita Y, Watanabe M, Hirahara I, et al. Level of 8-OHdG in drained dialysate appears to be a marker of peritoneal damage in peritoneal dialysis. Int J Nephrol Renovasc Dis. 2012; 5: 9-14
|
|
|
|
|
|
23）Soccal PM, Gasche Y, Pache JC, et al. Matrix metalloproteinases correlate with alveolar-capillary permeability alteration in lung ischemia-reperfusion injury. Transplantation. 2000; 70: 998-1005
|
|
|
|
|
|
24）Giebel SJ, Menicucci G, McGuire PG, et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest. 2005; 85: 597-607
|
|
|
|
|
|
25）郭 義胤, 野原 薫, 堤 康, 他． 小児PD患者におけるPET, 透析液MMP-2, IL-6などの腹膜機能マーカーの相互関連. 腎と透析. 2004; 57 別冊「腹膜透析2004」: 296-8
|
|
|
|
|
|
26）濱本幸浩, 高田俊彦, 蓑島謙一, 他．排液マーカー異常値と腹膜機能，腹膜炎発症回数についての臨床的検討. 腎と透析. 2006; 61 別冊「腹膜透析2006」: 324-6
|
|
|
|
|
|
27）Masunaga Y, Hirahara I, Shimano Y, et al. A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent. Clin Exp Nephrol. 2005; 9: 85-9
|
|
|
|
|
|
28）Ro Y, Hamada C, Io H, et al. Rapid, simple, and reliable method for the diagnosis of CAPD peritonitis using the new MMP-9 test kit. J Clin Lab Anal. 2004; 18 (4): 224-30
|
|
|
|
|
|
29）Takezawa Y, Saitou Y, Uchida T, et al. Matrix metalloproteinase levels in peritoneal effluents were increased in a patient with appendicitis undergoing continuous ambulatory peritoneal dialysis. Clin Exp Nephrol. 2012; 16: 501-4
|
|
|
|
|
|
30）Nishina M, Endoh M, Suzuki D, et al. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Clin Exp Nephrol. 2004; 8: 339-43
|
|
|
|
|
|
31）Minami S, Hora K, Kamijo Y, et al. Relationship between effluent levels of beta(2)-microglobulin and peritoneal injury markers in 7. 5% icodextrin-based peritoneal dialysis solution. Ther Apher Dial. 2007; 11: 296-300
|
|
|
|
|
|
32）梶原隆広, 古屋 徹, 大島直紀, 他．腹膜透析中止時マトリックスメタロプロテイナーゼ-2(MMP-2)が強陽性を示し半年後に腹水が貯留した長期腹膜透析患者の1例. 腎と透析. 2002; 53 別冊「腹膜透析2002」: 208-10
|
|
|
|
|
|
33）Moriishi M, Kawanishi H. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis. Adv Perit Dial. 2008; 24: 56-9
|
|
|
|
|
|
34）Yamamoto D, Takai S, Hirahara I, et al. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010; 411: 762-4
|
|
|
|
|
|
35）Yamamoto D, Takai S, Akimoto T, et al. Matrix metalloproteinase-2 inhibition by temocapril and its important role in peritoneal transport. Clin Exp Pharmacol Physiol. 2012; 39; 864-8
|
|
|
|
|